** Shares of drug developer Amplia Therapeutics ATX.AX
jump as much as 15.6% to A$0.185, their highest since Dec. 3,
2021
** Co says a contract manufacturer has completed
manufacturing of its clinical-stage drug candidate AMP945, a
pancreatic cancer and lung fibrosis drug urn:newsml:reuters.com:*:nASX15gs1t
** Mid-stage clinical trials for the drug scheduled to begin
in 2022
** Co has also doubled the scale at which AMP945 can be
manufactured under 'good manufacturing practice' conditions
** Co has found that AMP945 can be stored for more than 24
months without detectable deterioration, which supports
commercial development of the drug
** ATX set for its biggest intraday gain since Dec. 21, 2021
** Stock had lost 3% this year, as of last close
(Reporting by Harshita Swaminathan in Bengaluru)
((Harshita.Swaminathan@thomsonreuters.com))